Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
May 15, 2010 (Vol. 30, No. 10)

Single Use Becoming an Established Tool

Vendors' Attention to Users' Requirements and Familiarity Are Driving Increased Implementation

  • As single-use bioprocessing approaches its first decade, integration and standardization are on everyone’s short list of desirable features. Suppliers are responding with significant initiatives to streamline the specification, acquisition, assembly, and deployment of disposable equipment.

    Getting plastic components to work together with a minimum of validation has always been a priority. Now, it appears, acceptance may have reached a critical point and vendors are doing all they can to facilitate decision making by reducing or eliminating the interoperability question.

    At IBC Life Sciences’ upcoming “Single Use Applications for Biopharmaceutical Manufacturing,” a number of presenters will make their case for specific systems, components, or approaches that reflect their vision of the disposables marketplace.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »